Femasys Inc
NASDAQ:FEMY
Femasys Inc
Operating Income
Femasys Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Femasys Inc
NASDAQ:FEMY
|
Operating Income
-$17.8m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Operating Income
$2.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
10%
|
CAGR 10-Years
6%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Operating Income
$3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Stryker Corp
NYSE:SYK
|
Operating Income
$5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Operating Income
$7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Operating Income
$2.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
Femasys Inc
Glance View
Femasys, Inc. operates as a medical device company that focuses on women's healthcare. The company is headquartered in Suwanee, Georgia. The company went IPO on 2021-06-18. The firm is focused on providing women worldwide with non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. FemaSeed is an artificial insemination infertility treatment. The firm also offers FemVue Saline-Air device for diagnosis of infertility and FemCerv Endocervical Sampler for diagnosis of cervical cancer. FemCerv is a sterile, single-use disposable endocervical curettage product that can be used to sample cervical cells and tissue, including in support of further testing following an abnormal Pap test to assess for any problems such as cancer, in a relatively pain-free office procedure.
See Also
What is Femasys Inc's Operating Income?
Operating Income
-17.8m
USD
Based on the financial report for Dec 31, 2024, Femasys Inc's Operating Income amounts to -17.8m USD.
What is Femasys Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-9%
Over the last year, the Operating Income growth was -23%. The average annual Operating Income growth rates for Femasys Inc have been -29% over the past three years , -9% over the past five years .
You don't have any saved screeners yet